Dr. Glen Pyle
M.Sc Biomedical Sciences
B.Sc in Toxicology, University of Toronto 2009
Up to date, hormone replacement therapy (HRT) inspired by the beneficiary low risk of cardiovascular events among pre-menapausal women is yet to be elucidated. Contrary to convential knowledge of classic estrogen receptors, GPR30, once an orphan receptor, has been repeatedly reported to bind and respond to estrogen. My research interest is to study whether GPR30 activation by specific agonist G-1 would provide any immediate non-genomic benefits to the cardiac system, especially in terms of myofilament system.
Cardiac benefits of novel estrogen receptor GPR30 activation by G-1
International Society for Heart Research North American Section Meeting, 2006 & 2008.
Biophysical Society Annual Meeting, 2005.